<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18567" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Postmastectomy Breast Cancer Radiation Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Remick</surname>
            <given-names>Jill</given-names>
          </name>
          <aff>University of Maryland</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Amin</surname>
            <given-names>Neha P.</given-names>
          </name>
          <aff>University of Maryland School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jill Remick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Neha Amin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18567.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Postmastectomy radiation therapy (PMRT) is recommended for patients with more advanced breast cancer or certain high-risk pathologic features. In select patients, post-mastectomy radiation therapy has been shown to improve local control and overall survival. PMRT is directed at the chest wall and often includes the regional lymph nodes that drain the breast. This activity reviews the principles of post-mastectomy radiation therapy and the role of the interprofessional team in caring for patients undergoing it.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the mechanism of postmastectomy radiation therapy.</p></list-item><list-item><p>Identify appropriate candidates for postmastectomy radiation therapy.</p></list-item><list-item><p>Evaluate&#x000a0;the potential adverse effects of postmastectomy radiation therapy.</p></list-item><list-item><p>Communicate&#x000a0;a well-coordinated interprofessional team approach to provide effective care and appropriate monitoring to patients undergoing postmastectomy radiation therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18567&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18567">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18567.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A modified radical mastectomy is the primary treatment for women with locally advanced breast cancer. Additionally, some women with early-stage breast cancer may elect to undergo a mastectomy for cosmetic reasons, to avoid radiation potentially, or due to a genetic mutation that portends a higher risk for subsequent breast cancer. A mastectomy involves the removal of the whole breast. It is often paired with some axillary lymph node sampling (either sentinel lymph node biopsy or axillary node dissection of levels 1 and 2). Post-mastectomy radiation therapy (PMRT) is recommended for patients with more advanced disease or with certain high-risk pathologic features. PMRT has been shown to improve local control and overall survival in select patients. PMRT is directed at the chest wall and often includes the regional lymph nodes that drain the breast. This&#x000a0;topic&#x000a0;focuses on the&#x000a0;key aspects of PMRT.</p>
      </sec>
      <sec id="article-18567.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Locally advanced breast cancer encompasses a heterogeneous group of patients, including those with advanced primary tumor size, extensive or widespread nodal disease, and inflammatory breast cancer. In 2013, 30 to 40% of patients diagnosed with breast cancer had regional lymph node involvement, and 10% of patients had a primary tumor 5 centimeters or greater in size. Unlike most other malignancies, the prognosis for patients with locally advanced disease is favorable, with 5-year breast cancer-specific survival ranging from 78% to 90%.<xref ref-type="bibr" rid="article-18567.r1">[1]</xref></p>
      </sec>
      <sec id="article-18567.s4" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Indications for PMRT</bold>
</p>
        <p>Several large randomized trials have demonstrated a clinical benefit with the addition of postmastectomy radiation therapy in patients with high-risk diseases.<xref ref-type="bibr" rid="article-18567.r2">[2]</xref>&#x000a0;A large meta-analysis performed by the Early Breast Cancer Trialists&#x02019; Collaborative Group (EBCTCG) pooled individual patient data from 22 randomized trials comparing mastectomy, with or without adjuvant radiation therapy, and found that among patients with&#x000a0;4 or more positive notes, PMRT reduced locoregional recurrence by 19% which translated into a 9% reduction in breast cancer mortality&#x000a0;<xref ref-type="bibr" rid="article-18567.r3">[3]</xref>. The&#x000a0;2 largest studies included in this meta-analysis, the Danish collaborative group trials, randomized pre-and post-menopausal women with high-risk breast cancer, defined as any positive axillary lymph nodes, tumor size greater than 5 cm, or skin invasion, to undergo adjuvant chemotherapy with or without&#x000a0;postmastectomy radiation therapy.<xref ref-type="bibr" rid="article-18567.r2">[2]</xref>&#x000a0;These trials both showed an improvement in disease-free and overall survival with the addition of postmastectomy radiation therapy by approximately 10%, irrespective of tumor size or the number of lymph nodes involved. Therefore, the National Cancer Center Network (NCCN) recommends postmastectomy radiation therapy for patients with greater than or equal to 4 positive nodes.</p>
        <p>
<bold>Current controversies in PMRT</bold>
</p>
        <p>
<bold>Less than 4 positive lymph nodes</bold>
</p>
        <p>Despite earlier trials showing a consistent survival advantage for all node-positive patients, the validity of these findings among patients with less than 4 positive lymph nodes is often debated. The main criticisms of these trials were the use of less effective systemic therapies (ie, taxanes, dose-dense chemotherapy scheduling, HER2 targeted agents, and prolonged use of hormonal therapy were not consistently used) and inadequate axillary lymph node dissections. Furthermore, several other studies suggest the rate of locoregional recurrence among patients with 1 to 3 positive nodes is low&#x000a0;<xref ref-type="bibr" rid="article-18567.r4">[4]</xref><xref ref-type="bibr" rid="article-18567.r5">[5]</xref>.&#x000a0;An earlier study by Katz et al included over a thousand patients treated with mastectomy without adjuvant radiation and reported a locoregional failure rate of only 10% for a woman with 1 to 3 positive nodes. However, in the presence of other pathologic features, such as large tumor size, invasion of the skin/nipple, and close/positive margins, the risk of LRR was higher&#x000a0;<xref ref-type="bibr" rid="article-18567.r5">[5]</xref>.&#x000a0;A more recent analysis of more than 600 patients with 1 to 3 positive nodes enrolled on a randomized chemotherapy trial reported a 6.5% versus 2.5% rate of locoregional first recurrence after total mastectomy for those treated with or without postmastectomy radiation therapy, respectively&#x000a0;<xref ref-type="bibr" rid="article-18567.r6">[6]</xref>. A more modern series from the Cleveland Clinic reported a less than 10% locoregional failure rate among patients with 1 to 3 positive lymph nodes treated with mastectomy and chemotherapy without radiation&#x000a0;<xref ref-type="bibr" rid="article-18567.r7">[7]</xref>.</p>
        <p>Given the conflicting data, the NCCN recommends postmastectomy radiation therapy should be &#x0201c;strongly considered&#x0201d; in patients with 1 to 3 positive lymph nodes while also taking into account other clinical characteristics (ie, age, comorbidities, life expectancy), pathologic risk factors (ie tumor size, the ratio of positive lymph nodes, tumor grade, LVSI), and biologic tumor makeup (ie, hormonal receptor status and targetable mutations). These recommendations align with recently updated postmastectomy radiation therapy guidelines by a joint panel of the American Societies of Clinical, Radiation, and Surgical Oncology&#x000a0;<xref ref-type="bibr" rid="article-18567.r8">[8]</xref>. An ongoing, randomized trial in Europe (P88 MRC/EORTC BIG 2-04 SUPREMO) is evaluating the role of postmastectomy radiation therapy in intermediate-risk patients, including those with 1 to 3 positive nodes, by randomizing patients to receive postmastectomy radiation therapy or not.</p>
        <p>
<bold>T3N0</bold>
</p>
        <p>A similar controversy exists among node-negative patients with large primary tumor size (greater than 5 cm)&#x000a0;<xref ref-type="bibr" rid="article-18567.r9">[9]</xref>.&#x000a0;Isolated locoregional failure was as low as 7% among patients with T3N0 disease treated with mastectomy alone or with adjuvant systemic therapy in&#x000a0;5 NSABP chemotherapy trials&#x000a0;<xref ref-type="bibr" rid="article-18567.r9">[9]</xref>. Furthermore, a recent SEER analysis of 568 patients who received postmastectomy radiation therapy for T3N0 breast cancer showed no improvement in overall survival compared to a case-matched control analysis&#x000a0;<xref ref-type="bibr" rid="article-18567.r10">[10]</xref>. However, the risk of locoregional recurrence is higher in the presence of high-risk pathologic features, including LVSI, high tumor grade, close/positive margins, and premenopausal status, which again implies a subset of patients who may benefit from postmastectomy radiation therapy&#x000a0;<xref ref-type="bibr" rid="article-18567.r11">[11]</xref>.</p>
        <p>
<bold>Complete nodal response after neoadjuvant chemotherapy</bold>
</p>
        <p>Current recommendations for postmastectomy radiation therapy are based on the clinical stage before initiation of any therapy. However, an excellent/complete pathologic response to neoadjuvant chemotherapy in either the nodes or the breast is associated with a significantly decreased risk of locoregional recurrence&#x000a0;<xref ref-type="bibr" rid="article-18567.r12">[12]</xref>.&#x000a0;As a result, many argue these patients are effectively&#x000a0;down-staged to a lower risk category and thus may no longer derive a significant benefit from postmastectomy radiation therapy&#x000a0;<xref ref-type="bibr" rid="article-18567.r13">[13]</xref>.&#x000a0;This is the subject of an ongoing randomized controlled trial, NSABP B-51 (NCT01872975), in which patients with initial biopsy-proven positive lymph nodes (N1) that have a complete pathologic response to neoadjuvant chemotherapy are randomized to comprehensive regional nodal RT or chest wall radiation only. However, both NCCN and professional societies currently&#x000a0;state there is not enough evidence to support the omission of postmastectomy radiation therapy in these patients&#x000a0;<xref ref-type="bibr" rid="article-18567.r8">[8]</xref>.</p>
        <p>
<bold>Internal mammary node coverage</bold>
</p>
        <p>If internal mammary nodes (IMNs) are involved (ie, pathologically enlarged on CT and metabolically active on PET), they should be included in the radiation field. Elective IMN coverage is somewhat&#x000a0;controversial. In the earlier postmastectomy radiation therapy trials, the radiation portal encompassed all draining lymphatics of the breast, including the axillary, supraclavicular, and internal mammary nodal (IMN) chain&#x000a0;<xref ref-type="bibr" rid="article-18567.r2">[2]</xref>.&#x000a0;However, several studies have demonstrated an extremely low incidence of IMN nodal positivity and clinical IMN recurrence&#x000a0;<xref ref-type="bibr" rid="article-18567.r14">[14]</xref>.&#x000a0;Furthermore, the inclusion of the IMN chain within the radiation field comes at the expense of increased doses to the heart and lungs, resulting in a potentially greater risk of long-term toxicity.&#x000a0;</p>
        <p>Several large trials have evaluated the volume of elective nodal irradiation (ENI) volume to include in patients with centrally/medially located tumors, positive lymph nodes, or node-negative patients with&#x000a0;high-risk disease after mastectomy&#x000a0;<xref ref-type="bibr" rid="article-18567.r15">[15]</xref>.&#x000a0;Studies from France and Denmark specifically addressed the benefit of internal mammary node irradiation (IMNI) by comparing outcomes of patients treated with a whole breast, chest wall radiation, supraclavicular, and axillary apex with or without IMNI&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="0">[23]</ext-link><xref ref-type="bibr" rid="article-18567.r16">[16]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="0">.</ext-link>&#x000a0;While the French study was randomized, the Dutch study allocated IMNI only to patients with right-sided disease and omitted IMNI in left-sided disease to save the dose to the heart. The Dutch study reported a small but significant 2.5% improvement in breast cancer-specific survival for right-sided breast cancer patients allocated to IMNI&#x000a0;<xref ref-type="bibr" rid="article-18567.r17">[17]</xref>.&#x000a0;In contrast, the French randomized trial failed to show a survival benefit&#x000a0;<xref ref-type="bibr" rid="article-18567.r18">[18]</xref>.&#x000a0;Another large randomized trial, EORTC 22922, evaluated comprehensive nodal irradiation (including IMN) compared to standard breast radiation alone in patients with high-risk node-negative, central/medially located tumors, or positive lymph nodes. This study demonstrated a 3% improvement in disease-free survival and a 2% reduction in breast cancer mortality; however, only about one-fourth of these patients had undergone mastectomy&#x000a0;<xref ref-type="bibr" rid="article-18567.r15">[15]</xref>.</p>
        <p>In summary, comprehensive lymph node coverage has yielded mixed results but may offer a small improvement in disease-free and possibly even breast cancer-specific survival. Given the insufficient evidence, a multidisciplinary expert panel on post-mastectomy management suggests that if comprehensive nodal radiation is recommended, the radiation treatment field should include the IMN, supraclavicular, and apical axillary regions, as well as the chest wall&#x000a0;<xref ref-type="bibr" rid="article-18567.r8">[8]</xref>.</p>
        <p>
<bold>Postmastectomy radiation therapy&#x000a0;</bold>
<bold>after implant/tissue expander</bold>
</p>
        <p>Postmastectomy radiation therapy after breast reconstruction has been associated with increased rates of capsular contracture, reconstructive failures, revision surgeries, and overall worse cosmetic outcomes&#x000a0;<xref ref-type="bibr" rid="article-18567.r19">[19]</xref>.&#x000a0;The timing of the breast reconstruction (ie, immediate versus delayed) and type of breast reconstruction (ie, autologous versus implant-based) are important considerations that require an informative discussion with the patient and multi-disciplinary team before surgery.</p>
        <p>Most often, implant reconstruction occurs in&#x000a0;2 phases, with the placement of a tissue expander followed by a permanent implant. Several studies evaluating the optimal sequence of 2-phase reconstruction with radiotherapy have demonstrated higher rates of reconstructive failures ranging from 32% to 40% when radiation was delivered to the tissue expander compared to radiation directed at the permanent implant&#x000a0;<xref ref-type="bibr" rid="article-18567.r20">[20]</xref>.&#x000a0;Interestingly, a prospective study from the Mastectomy Reconstruction Outcomes Consortium (MROC) found no difference in major complication rates between tissue-expander versus implant-directed radiotherapy and reported an overall failure rate of 10%&#x000a0;<xref ref-type="bibr" rid="article-18567.r21">[21]</xref>.&#x000a0;Therefore, patients who elect to undergo immediate expander/implant reconstruction should be carefully evaluated to determine the potential need for postmastectomy radiation therapy and should be thoroughly counseled regarding the risks in the setting of breast reconstruction.</p>
      </sec>
      <sec id="article-18567.s5" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>
<bold>Simulation and Treatment Volumes</bold>
</p>
        <p>Patients are simulated in the supine position with their arms raised above their heads. Immobilization devices, such as a wingboard with a vacuum bag, can support the arms and neck and replicate the same position during daily treatments. The head is turned up and away from the treated breast to remove the chin from the beam divergence. The mastectomy scar is often delineated with a radio-opaque marker to make sure the entire scar is included in the radiation plan. The medial, lateral (mid-axillary line), superior (caudal edge of the clavicle), and inferior (1 to 2 cm below the inframammary line) field borders can also be delineated with a radio-opaque marker to guide initial beam placement. For patients with&#x000a0;left-sided breast cancer, deep-inspiratory breath hold, a technique in which patients are instructed to hold their breath for 20 to 30 seconds at peak inspiration, can often increase the distance between the heart and chest wall, thus lowering the cardiac dose. If this technique is considered, testing a patient&#x02019;s ability to perform this exercise should be done during simulation. Several contouring atlases are available for chest wall and nodal delineation, including the Radiation Therapy Oncology Group (RTOG)&#x000a0;<xref ref-type="bibr" rid="article-18567.r22">[22]</xref>&#x000a0;and&#x000a0;RADCOMP (NCT02603341), among others&#x000a0;<xref ref-type="bibr" rid="article-18567.r16">[16]</xref>.&#x000a0;For lymph node volume delineation, contouring guidelines differ slightly regarding anatomical reference points and vessel-based approaches.</p>
        <p>
<bold>General volume delineation guidelines for the chest wall</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The chest wall clinical target volume (CTV) should be contoured to the muscle-rib interface to include the pectoralis muscles and the entire scar plus margin. The cranial border extends to the caudal border of the clavicular head, which is clinically determined based on markers placed at the time of simulation and using the contralateral breast as a guide. The lateral border typically extends to the mid-axillary line and the medial border to the sternal-rib junction to avoid crossing the midline.</p>
          </list-item>
          <list-item>
            <p>If image guidance is used during treatments, the chest wall planning target volume (PTV) is created by expanding the CTV by 0.5 cm. Otherwise, the CTV to PTV expansion ranges from 0.5 to 1 cm. To ensure chest wall dose, the PTV can extend into the ribs about 2 mm.</p>
          </list-item>
        </list>
        <p>
<bold>General volume delineation guidelines for lymph nodes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Axillary levels 1 through 3 are demarcated relative to the pectoralis minor muscle, axillary vessels in which level 1 lies lateral and inferior, level 2 lies posterior, and level 3 lies superior-medial.</p>
          </list-item>
          <list-item>
            <p>The supraclavicular (SCV) lymph nodes lie superior to level 3 and commence just caudal to the cricoid cartilage. SVC nodes extend inferiorly to the caudal edge of the clavicular head, laterally to the lateral edge of the sternocleidomastoid or junction of the&#x000a0;1 rib with the clavicle, and medially, it excludes the thyroid and trachea.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If treating the internal mammary nodes with IMRT, the first&#x000a0;3 intercostal spaces should be contoured.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>When using image guidance, PTV for the lymph nodes is generated by expanding the CTV by 0.5 cm.</p>
          </list-item>
        </list>
        <p>
<bold>Radiation Planning Technique</bold>
</p>
        <p>Patient anatomy, target volume, dose constraints, and physician preference are used to determine the optimal radiation technique. Below is a description of various radiation techniques.</p>
        <p>
<bold>3D conformation radiation therapy (3DCRT)</bold>
</p>
        <p>The most commonly used treatment technique for PMRT is a forward-planned technique using photons called 3D conformation radiation therapy (3DCRT). The dosimetrist and radiation oncologist often use 3 to 5 beams to treat the chest wall and regional lymphatics. To create a customized plan for each patient, the dosimetrist and radiation oncologist work together to determine the best beam angle, field size, blocks, beam energy, and weighting.&#x000a0;The radiation field setup for a typical plan is discussed below:</p>
        <list list-type="bullet">
          <list-item>
            <p>The chest wall is treated with&#x000a0;2 opposing tangential fields. The superior field edge of the tangential fields is often just below the clavicular head, and the inferior field edge of the supraclavicular field (discussed below). The tangents should be placed at an angle to avoid the contralateral breast and minimize the dose to the heart and lungs, ideally with less than 1 cm (or no heart) in the field and less than 2 cm of the lung in the field.</p>
          </list-item>
          <list-item>
            <p>The supraclavicular and Level 3 lymph node volumes are treated with a single oblique anterior supraclavicular field, often angled 10 to 15 degrees away from the midline, to avoid overlapping the spinal cord and esophagus. The multileaf collimator blocks the acromioclavicular joint and part of the humeral head. The beam's energy can be adjusted so that the 45 Gray (Gy) line reaches the posterior edge of the lymph node volumes. An optional posterior axillary &#x0201c;boost&#x0201d; field may be added to increase deep axillary coverage or to reduce hot spots from a single anterior field.</p>
          </list-item>
          <list-item>
            <p>A direct matched electron or photon field can cover the internal mammary chain. Alternatively, the tangents can be partially widened superiorly to cover the top&#x000a0;3 intercostal spaces encompassing the internal mammary nodes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>&#x000a0;An even, non-divergent match line between the tangential chest wall beams and the anterior supraclavicular beam is generated by using a half-beam block (one isocenter technique) or by angling the couch (couch-kick) to create a horizontal match line between the tangential and supraclavicular field edges (2 isocenter technique).</p>
          </list-item>
        </list>
        <p>
<bold>Intensity-modulated radiation therapy (IMRT)</bold>
</p>
        <p>Intensity-modulated radiation therapy (IMRT)&#x000a0;is generally considered when heart or lung dose-volume constraints with 3DCRT planning are unmet. IMRT is an inverse planning technique using photons. This means that after the target and normal structures are contoured, the dosimetrist enters the goals of coverage and limits to normal structures, and the radiation treatment planning system runs to optimize the plan. IMRT typically involves a greater number of beams compared to 3DCRT. Volumetric modulated therapy (VMAT) is the IMRT technique that employs continuous arcs during treatment. While VMAT can be very conformal, it does result in the expansive spread of low dose to a larger volume of normal structures compared to a 3DCRT plan due to the exit dose of the photon beam arc.</p>
        <p>
<bold>Intensity-modulated proton therapy (IMPT)</bold>
</p>
        <p>Protons are heavy ions that deposit the maximum dose at a specific distance in tissue (Bragg Peak), after which no dose is deposited into the tissue. In other words, there is no exit dose when using proton therapy, resulting in possibly less dose to normal tissues and, therefore, has the potential to reduce long-term side effects. This contrasts photon beams with an entry and exit dose&#x000a0;<xref ref-type="bibr" rid="article-18567.r23">[23]</xref>.&#x000a0;Clinical experience with proton therapy for postmastectomy radiation therapy primarily involves patients with left-sided lesions or those that require regional nodal irradiation (RNI)&#x000a0;<xref ref-type="bibr" rid="article-18567.r24">[24]</xref>.&#x000a0;Reported mean heart dose, mean heart V5, and mean lung V20 from select studies are less than or equal to 1 Gy, 3% to 7%, and 13% to 28%&#x000a0;<xref ref-type="bibr" rid="article-18567.r24">[24]</xref><xref ref-type="bibr" rid="article-18567.r25">[25]</xref>. Proton treatment planning involving the chest wall and lymphatics commonly employs&#x000a0;2 enface proton beams to cover the targets. The treatment planning system then optimizes the plan and accounts for uncertainties pertaining to dose calibration using Hounsfield units (HU) and proton end range. Comparison of conventional photon versus proton radiation in comprehensive breast irradiation is an area of ongoing research. A nationwide randomized trial, RADCOMP (NCT02603341), is actively accruing patients with locally advanced breast cancer who require RNI after either mastectomy or breast conservation surgery to receive either photon or proton therapy. The primary endpoint of this study is a reduction in major cardiovascular events at 10 years. Other assessment endpoints include long-term disease control, survival, and quality of life.</p>
        <p>
<bold>Radiation Dosing and Fractionation</bold>
</p>
        <p>Conventional dosing for PMRT is 50-50.4 Gy in 1.8-2.0 Gy per fraction (25-28 total fractions) to the chest wall and 45-50 Gy in 1.8-2.0 Gy per fraction (25 total fractions) to the regional lymph nodes. Hypofractionation, which involves giving a larger daily dose over a shorter period (fewer total fractions), is an active area of research in the post-mastectomy setting to reduce treatment costs and increase patient convenience. The Alliance Group is currently evaluating the effect of hypofractionated PMRT in breast reconstruction, with the primary endpoint being the 2-year reconstructive complication rate (NCT03414970). In this study, patients with stage IIA-IIIA breast cancer who have undergone mastectomy and breast reconstruction are randomized to receive either standard daily radiation therapy for 5 to 6 weeks or daily radiotherapy given over a shortened course of 3 to 4 weeks. Further dose hypofractionation for postmastectomy radiation therapy is being explored in the United Kingdom (FAST-Forward). This phase III, multicenter, randomized controlled trial (FAST-Forward) is evaluating&#x000a0;2 different 5-fraction PMRT dosing regimens (27 Gy or 26 Gy in 5 fractions) compared to standard control (40.05 Gy in 15 fractions).&#x000a0;</p>
        <p>Since photons require tissue interaction to build up the dose, the dose at the skin surface is lower than the dose at the target. A chest wall bolus may be used to increase the skin dose for patients who have an increased risk of chest wall recurrence (ie, large tumors, positive/close margins, inflammatory breast cancer). In general, a 0.5 cm tissue equivalent bolus can be used every other day to increase the skin to 85% of the prescription dose, or in cases of inflammatory breast cancer, a daily bolus can be used to ensure the skin dose reaches 95% of the prescribed dose. Alternatively, a single sheet of brass bolus (2-sheet thickness for inflammatory/T4 tumors) can be used daily and is equivalent to 0.5 cm tissue equivalent bolus every other day. A mastectomy scar boost to 10 to 16 Gy in 5 to 8 fractions is considered in the presence of close (less than 2 mm) or positive margins, and for inflammatory breast cancer, however, a boost is generally avoided in patients planned for reconstruction if they don&#x02019;t have other risk factors for recurrence.&#x000a0;</p>
        <p>
<bold>Plan Evaluation </bold>
</p>
        <p>Radiation oncologists work with dosimetrists to customize the plan to the patient&#x02019;s anatomy and targets using the abovementioned options. The radiation oncologist then evaluates the plan to assess the adequacy of target coverage while minimizing the dose to the lung, heart, and other nearby tissues using the dose-value recommendations.</p>
      </sec>
      <sec id="article-18567.s6" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Radiation Toxicity</bold>
</p>
        <p>In general, postmastectomy radiation therapy&#x000a0;is very well tolerated, and patients can continue their normal routine. It does not lead to decreased immunity or feelings of illness, and patients are not radioactive; therefore, they are safe to be around other people. Adverse effects or toxicity associated with postmastectomy radiation therapy is discussed in terms of acute and chronic.</p>
        <p>
<bold>Acute Toxicity</bold>
</p>
        <p>Acute toxicity is generally defined as occurring during and within 3 months of radiation treatment. The most common adverse effects include fatigue, temporary sore throat, and radiation dermatitis. Radiation dermatitis&#x000a0;gradually develops as more radiation treatments are delivered. It can include skin erythema, hyperpigmentation, rash, and dryness followed by moist desquamation. Skin toxicity may peak in intensity 1 to 2 weeks after the end of&#x000a0;treatment. Patients are advised to keep their skin moisturized during radiation to help with the daily healing of healthy skin tissue. Other topical agents like aloe, hydrocortisone, or silver sulfadiazine can help with burning, itching, and desquamation of the skin. If a patient develops large confluent areas of moist desquamation, hydrogel or hydrocolloid dressings can be applied. The skin should be monitored regularly for signs and symptoms of infection. A skin bolus is typically removed during brisk erythema or moist desquamation. Generally, the skin is well healed 2 to 4 weeks after treatment, although some patients have residual long-term skin hyperpigmentation and subcutaneous fibrosis throughout the treatment field.</p>
        <p>
<bold>Chronic Toxicity </bold>
</p>
        <p>Common chronic or long-term toxicity associated with postmastectomy radiation therapy includes hyperpigmentation and fibrosis of the chest wall, affecting cosmetic outcomes after reconstruction (breast implant). Other potential long-term toxicities include minor risks of radiation pneumonitis (higher when treating comprehensive lymph nodes), rib fracture, arm lymphedema, radiation-induced heart disease (RIHD) (particularly for left-sided treatments), hypothyroidism (if treating supraclavicular region), and an extremely low risk of secondary malignancy. The management of arm lymphedema and the risk of&#x000a0;RIHD&#x000a0;is discussed in more detail below. Chronic arm lymphedema is a very challenging complication of postmastectomy radiation therapy, and thus, prevention and early intervention are key. Early signs of lymphedema include swelling, limb heaviness, aching, tightness, and fatigue. The risk of lymphedema after axillary RT ranges from 11% to 15% at 1 to 5 years post-treatment and is significantly higher in the setting of prior axillary dissection&#x000a0;<xref ref-type="bibr" rid="article-18567.r26">[26]</xref>.&#x000a0;Lymphedema education, compression sleeves, compression pumps, regular exercise, and personal preventive measures have been shown to reduce the incidence of breast cancer-related lymphedema&#x000a0;<xref ref-type="bibr" rid="article-18567.r27">[27]</xref>.</p>
        <p>The most worrisome late side effect of postmastectomy radiation therapy is the increased risk of cardiac disease. Data to support dose-volume constraints for normal tissues are limited. The ongoing national randomized trial, RADCOMP, recommends general dose-volume constraints. An early landmark trial by Darby et al demonstrated a linear correlation between dose to the heart and rate of major coronary events. In this analysis, for every 1 Gy increase in mean dose to the heart, the relative rate of major coronary events increased by 7.4% and was observed as early as 5 years and continued up to 20 years after treatment&#x000a0;<xref ref-type="bibr" rid="article-18567.r28">[28]</xref>. However, this risk is thought to be less with more modern radiation techniques. A more recent analysis of individual patient data published between 2010 and 2015 reported average whole lung and heart doses of 5.7 Gy and 4.4 Gy, respectively <xref ref-type="bibr" rid="article-18567.r29">[29]</xref>.&#x000a0;Among patients treated before the year 2000, the risk of cardiac mortality was increased (RR 1.3), corresponding to a 4% increased incidence of cardiac mortality per Gy mean heart dose.</p>
        <p>Proton beam therapy may reduce the dose to the heart and lungs, particularly when treating comprehensive lymph nodes. There have been several dosimetric comparison studies between 3D conformal, IMRT, and proton beam therapy and comparisons of passive scatter and pencil beam technology&#x000a0;<xref ref-type="bibr" rid="article-18567.r30">[30]</xref>.&#x000a0;These studies have shown a reduction in dose to the heart and lung with proton therapy, particularly when IMNs are treated; however, the clinical impact of this dose reduction is unknown. An ongoing randomized trial, RADCOMP (NCT02603341), evaluates these dose effects by randomizing patients who require comprehensive nodal irradiation to receive either proton or photon therapy, with the primary endpoint being a reduction in late cardiac mortality. Deep inspiratory breath hold is another technique to reduce the radiation dose to the heart by creating lung airspace between the chest wall and mediastinum.</p>
      </sec>
      <sec id="article-18567.s7" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about this topic are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Postmastectomy radiation therapy (PMRT) is associated with a decrease in locoregional recurrence and an improvement in overall survival among patients with high-risk pathologic features, including positive lymph nodes, positive margins, and inflammatory breast cancer.</p>
          </list-item>
          <list-item>
            <p>There is controversy over the benefit of PMRT in patients with T3N0 breast cancer, however, the risk of recurrence is increased in the presence of other high-risk pathologic features such lymphovascular invasion, high tumor grade, close or positive margins, and premenopausal status.</p>
          </list-item>
          <list-item>
            <p>Target volume should include the chest wall and comprehensive lymph node areas, which include the axillary, supraclavicular, and internal mammary lymph nodes. If all lymph nodes are negative and the patient has a positive margin, then the chest wall alone can be the target. Studies evaluating the role of comprehensive lymph node coverage have demonstrated a small improvement in disease-free survival and overall survival; however, this comes at the cost of increased dose to the heart.</p>
          </list-item>
          <list-item>
            <p>3D conformal radiation therapy (3D CRT) and intensity-modulated radiation therapy (IMRT) are&#x000a0;2 of the most common treatment techniques used for postmastectomy radiotherapy. Several different consensus guidelines for target volume delineation exist.</p>
          </list-item>
          <list-item>
            <p>Long-term side effects of PMRT include an increased risk of heart disease and secondary malignancy. Deep-inspiratory breath hold is used to reduce the radiation dose to the heart. Proton beam therapy can potentially reduce the dose to the heart and normal tissue and is currently&#x000a0;an active area of research.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18567.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There is good evidence that post-mastectomy radiation lowers the risk of locoregional recurrence of breast cancer. However, this therapy is not devoid of side effects. Patients undergoing radiation therapy must be managed by an interprofessional team that includes an oncologist, an oncology nurse, a physical therapist, and an internist. These patients need follow-up to ensure that they are not developing a recurrence of cancer or side effects from the therapy. Besides history and physical exam, a mammogram and routine blood tests are required every 6 to 12 months. In addition, women over 60 also need an assessment of their bone density. To reduce the risk of fractures, the patient should be encouraged to discontinue smoking and enroll in a physical therapy program. A cardiology referral is necessary to screen for heart disease. The pharmacist should emphasize the importance of integrative therapies like yoga, meditation, massage, and music to lower stress. A dietary consult should be&#x000a0;obtained to ensure the patient eats a healthy diet rich in calcium.<xref ref-type="bibr" rid="article-18567.r31">[31]</xref><xref ref-type="bibr" rid="article-18567.r32">[32]</xref></p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>There have been many studies conducted on the benefits of post-mastectomy radiation, and the overall impression is that there is a reduction in relapse rates and overall mortality in patients who receive extensive irradiation. So far, the studies have not shown a significant difference in recurrence following radiation in patients with&#x000a0;1 or 2-3 positive&#x000a0;lymph nodes. Unfortunately, most studies have not been long-term, with only a few following patients at 10 years.<xref ref-type="bibr" rid="article-18567.r33">[33]</xref><xref ref-type="bibr" rid="article-18567.r6">[6]</xref></p>
      </sec>
      <sec id="article-18567.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18567&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18567">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/postmastectomy-breast-cancer-radiation-therapy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18567">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18567/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18567">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18567.s10">
        <title>References</title>
        <ref id="article-18567.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Gail</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Sep</month>
            <day>10</day>
            <volume>33</volume>
            <issue>26</issue>
            <fpage>2870</fpage>
            <page-range>2870-6</page-range>
            <pub-id pub-id-type="pmid">26195709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overgaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Overgaard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kjaer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gadeberg</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Mouridsen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Zedeler</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.</article-title>
            <source>N Engl J Med</source>
            <year>1997</year>
            <month>Oct</month>
            <day>02</day>
            <volume>337</volume>
            <issue>14</issue>
            <fpage>949</fpage>
            <page-range>949-55</page-range>
            <pub-id pub-id-type="pmid">9395428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>EBCTCG (Early Breast Cancer Trialists' Collaborative Group)</collab>
              <name>
                <surname>McGale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cutter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Duane</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ewertz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mannu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Darby</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>Jun</month>
            <day>21</day>
            <volume>383</volume>
            <issue>9935</issue>
            <fpage>2127</fpage>
            <page-range>2127-35</page-range>
            <pub-id pub-id-type="pmid">24656685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Recht</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Fowble</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Solin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Falkson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Falkson</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Tormey</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.</article-title>
            <source>J Clin Oncol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1689</fpage>
            <page-range>1689-700</page-range>
            <pub-id pub-id-type="pmid">10561205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Theriault</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singletary</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>McNeese</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2001</year>
            <month>Jul</month>
            <day>01</day>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>735</fpage>
            <page-range>735-42</page-range>
            <pub-id pub-id-type="pmid">11395242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeidan</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ameye</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paesmans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Azambuja</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nordenskj&#x000f6;ld</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lluch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gnant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldhirsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Leo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Crown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Piccart-Gebhart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>316</fpage>
            <page-range>316-324</page-range>
            <pub-id pub-id-type="pmid">29534902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tendulkar</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shukla</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Budd</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Dietz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Macklis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2012</year>
            <month>Aug</month>
            <day>01</day>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>e577</fpage>
            <page-range>e577-81</page-range>
            <pub-id pub-id-type="pmid">22560546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Recht</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Comen</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Hardenbergh</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Hudis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kirshner</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salerno</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Sledge</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Solin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Spears</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Somerfield</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Edge</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.</article-title>
            <source>Pract Radiat Oncol</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>e219</fpage>
            <page-range>e219-e234</page-range>
            <pub-id pub-id-type="pmid">27659727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taghian</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mamounas</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Parda</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Costantino</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wolmark</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Aug</month>
            <day>20</day>
            <volume>24</volume>
            <issue>24</issue>
            <fpage>3927</fpage>
            <page-range>3927-32</page-range>
            <pub-id pub-id-type="pmid">16921044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Castrucci</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Weidhaas</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology, and End Results database.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Jul</month>
            <day>01</day>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-47</page-range>
            <pub-id pub-id-type="pmid">18442108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Floyd</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Haffty</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niemierko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raad</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oswald</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taghian</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>358</fpage>
            <page-range>358-64</page-range>
            <pub-id pub-id-type="pmid">16887288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mamounas</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dignam</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bear</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Geyer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Taghian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wickerham</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wolmark</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Nov</month>
            <day>10</day>
            <volume>30</volume>
            <issue>32</issue>
            <fpage>3960</fpage>
            <page-range>3960-6</page-range>
            <pub-id pub-id-type="pmid">23032615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mamounas</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>20</day>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>494</fpage>
            <page-range>494-5</page-range>
            <pub-id pub-id-type="pmid">24378411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heuts</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>van der Ent</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>von Meyenfeldt</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Voogd</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Internal mammary lymph drainage and sentinel node biopsy in breast cancer - A study on 1008 patients.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>252</fpage>
            <page-range>252-7</page-range>
            <pub-id pub-id-type="pmid">18684584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poortmans</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Collette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kirkove</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van Limbergen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Budach</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Struikmans</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Collette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fourquet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maingon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Valli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Winter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marnitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barillot</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Scandolaro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vonk</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rodenhuis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marsiglia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Tienhoven</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Glanzmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arriagada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bartelink</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Van den Bogaert</surname>
                <given-names>W</given-names>
              </name>
              <collab>EORTC Radiation Oncology and Breast Cancer Groups</collab>
            </person-group>
            <article-title>Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>23</day>
            <volume>373</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-27</page-range>
            <pub-id pub-id-type="pmid">26200978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhoeven</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weltens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Remouchamps</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mahjoubi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Veldeman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lengel&#x000e9;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hortobagyi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kirkove</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vessel based delineation guidelines for the elective lymph node regions in breast cancer radiation therapy - PROCAB guidelines.</article-title>
            <source>Radiother Oncol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>118</volume>
            <issue>1</issue>
            <fpage>209</fpage>
            <page-range>209-10</page-range>
            <pub-id pub-id-type="pmid">26743831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorsen</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Offersen</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Dan&#x000f8;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Brodersen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Overgaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Overgaard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Feb</month>
            <day>01</day>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>314</fpage>
            <page-range>314-20</page-range>
            <pub-id pub-id-type="pmid">26598752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hennequin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bossard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Servagi-Vernat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maingon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dubois</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Datchary</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carrie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roullet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suchaud</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Teissier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lucardi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gerard</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Belot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iwaz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ecochard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romestaing</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2013</year>
            <month>Aug</month>
            <day>01</day>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>860</fpage>
            <page-range>860-6</page-range>
            <pub-id pub-id-type="pmid">23664327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christante</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pommier</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Diggs</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Samuelson</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marquez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vetto</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pommier</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Using complications associated with postmastectomy radiation and immediate breast reconstruction to improve surgical decision making.</article-title>
            <source>Arch Surg</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>145</volume>
            <issue>9</issue>
            <fpage>873</fpage>
            <page-range>873-8</page-range>
            <pub-id pub-id-type="pmid">20855758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nava</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Pennati</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Lozza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Spano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zambetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catanuto</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Outcome of different timings of radiotherapy in implant-based breast reconstructions.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>128</volume>
            <issue>2</issue>
            <fpage>353</fpage>
            <page-range>353-359</page-range>
            <pub-id pub-id-type="pmid">21788827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santosa</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>TNS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hamill</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bensenhaver</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pusic</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>Postmastectomy Radiation Therapy and Two-Stage Implant-Based Breast Reconstruction: Is There a Better Time to Irradiate?</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>138</volume>
            <issue>4</issue>
            <fpage>761</fpage>
            <page-range>761-769</page-range>
            <pub-id pub-id-type="pmid">27673513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gentile</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Usman</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Neuschler</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Sathiaseelan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Contouring Guidelines for the Axillary Lymph Nodes for the Delivery of Radiation Therapy in Breast Cancer: Evaluation of the RTOG Breast Cancer Atlas.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2015</year>
            <month>Oct</month>
            <day>01</day>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-65</page-range>
            <pub-id pub-id-type="pmid">26383674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patyal</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Dosimetry aspects of proton therapy.</article-title>
            <source>Technol Cancer Res Treat</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>4 Suppl</issue>
            <fpage>17</fpage>
            <page-range>17-23</page-range>
            <pub-id pub-id-type="pmid">17668947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer.</article-title>
            <source>Clin Breast Cancer</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>145</fpage>
            <page-range>145-54</page-range>
            <pub-id pub-id-type="pmid">26995159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacDonald</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hickey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isakoff</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gadd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Yeap</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Kooy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Taghian</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2013</year>
            <month>Jul</month>
            <day>01</day>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>484</fpage>
            <page-range>484-90</page-range>
            <pub-id pub-id-type="pmid">23523326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Tienhoven</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Straver</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Meijnen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van de Velde</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Mansel</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Cataliotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Westenberg</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Klinkenbijl</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Orzalesi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bouma</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>van der Mijle</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Nieuwenhuijzen</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Veltkamp</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Slaets</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Duez</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>van Dalen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marinelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rijna</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Snoj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bundred</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Merkus</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Belkacemi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Petignat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schinagl</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Coens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Bogaerts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rutgers</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>1303</fpage>
            <page-range>1303-10</page-range>
            <pub-id pub-id-type="pmid">25439688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Incidence and risk factors of breast cancer lymphoedema.</article-title>
            <source>J Clin Nurs</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1450</fpage>
            <page-range>1450-9</page-range>
            <pub-id pub-id-type="pmid">18482142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darby</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ewertz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bennet</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Blom-Goldman</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Br&#x000f8;nnum</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cutter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gagliardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gigante</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Nisbet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rahimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Risk of ischemic heart disease in women after radiotherapy for breast cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Mar</month>
            <day>14</day>
            <volume>368</volume>
            <issue>11</issue>
            <fpage>987</fpage>
            <page-range>987-98</page-range>
            <pub-id pub-id-type="pmid">23484825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duane</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Aznar</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bergh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dodwell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ewertz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jagsi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Swain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McGale</surname>
                <given-names>P</given-names>
              </name>
              <collab>Early Breast Cancer Trialists&#x02019; Collaborative Group</collab>
            </person-group>
            <article-title>Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>May</month>
            <day>20</day>
            <volume>35</volume>
            <issue>15</issue>
            <fpage>1641</fpage>
            <page-range>1641-1649</page-range>
            <pub-id pub-id-type="pmid">28319436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ares</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Macartain</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Heuberger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goitein</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lutters</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hug</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Bodis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lomax</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements?</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2010</year>
            <month>Mar</month>
            <day>01</day>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>685</fpage>
            <page-range>685-97</page-range>
            <pub-id pub-id-type="pmid">19615828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arciero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meisel</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary Approaches to Chest Wall Recurrences of Breast Cancer.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2018</year>
            <month>Aug</month>
            <day>15</day>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>392</fpage>
            <page-range>392-6, 417</page-range>
            <pub-id pub-id-type="pmid">30153317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grossmith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Plichta</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Nakhlis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cutone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dominici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Golshan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duggan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rhei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barbie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Calvillo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nimbkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bellon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Punglia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>3527</fpage>
            <page-range>3527-3534</page-range>
            <pub-id pub-id-type="pmid">29868979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18567.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Rahman</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : An individual patient data analysis of three clinical trials.</article-title>
            <source>Strahlenther Onkol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>195</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-305</page-range>
            <pub-id pub-id-type="pmid">30069737</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
